Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) and Audentes Therapeutics Inc. (NASDAQ:BOLD), are influenced by compare since they are both players in the Biotechnology. These factors are particularly influence the institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations of the two firms.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cyclacel Pharmaceuticals Inc.	N/A	0.00	7.51M	-0.63	0.00
Audentes Therapeutics Inc.	N/A	0.00	128.82M	-2.72	0.00

Table 1 shows top-line revenue, earnings per share (EPS) and valuation of the two companies.

Profitability

Table 2 hightlights the return on equity, net margins and return on assets of the two companies.

	Net Margins	Return on Equity	Return on Assets
Cyclacel Pharmaceuticals Inc.	0.00%	-38.8%	-31.9%
Audentes Therapeutics Inc.	0.00%	-36.6%	-33.9%

Liquidity

The Current Ratio and Quick Ratio of Cyclacel Pharmaceuticals Inc. are 5.2 and 5.2 respectively. Its competitor Audentes Therapeutics Inc.’s Current Ratio is 14.8 and its Quick Ratio is 14.8. Audentes Therapeutics Inc. can pay off short and long-term obligations better than Cyclacel Pharmaceuticals Inc.

Institutional & Insider Ownership

Cyclacel Pharmaceuticals Inc. and Audentes Therapeutics Inc. has shares owned by institutional investors as follows: 4.1% and 0%. Insiders owned 18.62% of Cyclacel Pharmaceuticals Inc. shares. Insiders Comparatively, owned 1.3% of Audentes Therapeutics Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Cyclacel Pharmaceuticals Inc.	3.95%	6.58%	-4.32%	-44.24%	-44.97%	39.17%
Audentes Therapeutics Inc.	18.9%	40.28%	43.46%	-2.66%	2.02%	63.18%

For the past year Cyclacel Pharmaceuticals Inc. was less bullish than Audentes Therapeutics Inc.

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The companyÂ’s oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; and Phase II clinical trial for the treatment of myelodysplastic syndromes. Its oncology development programs also comprise Seliciclib, a first-generation cyclin dependent kinase (CDK) inhibitor that is in phase I/II combination study with sapacitabine for BRCA mutations; and CYC065, a second generation CDK inhibitor, which is in Phase I clinical trial for solid tumors. In addition, the companyÂ’s oncology development programs include CYC140, a polo-like kinase inhibitor program that is in preclinical development stage. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.

Audentes Therapeutics, Inc., a biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects in the United States. The company is developing AT132 for the treatment of X-linked myotubular myopathy; AT342 for the treatment of crigler-najjar syndrome type 1; AT982 for the treatment of pompe disease; and AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. Audentes Therapeutics, Inc. has a collaboration with the University of Pennsylvania for the treatment of Crigler-Najjar. The company was founded in 2012 and is headquartered in San Francisco, California.